Free Trial
→ SpaceX minted 4400 millionaires in a single day (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entegris, Inc. stock logo
ENTG
Entegris
$138.74
-5.5%		$147.53
$67.97
▼
$186.94
$22.40B1.42.22 million shs2.71 million shs
LBL
Lattice Biologics
C$0.04
C$0.04
C$0.03
▼
C$0.13
C$5.13MN/A468,022 shs114,000 shs
Indiva Limited stock logo
NDVA
Indiva
C$0.03
-14.3%		C$0.03
C$0.02
▼
C$0.13
C$5.87M1.12119,038 shs558,384 shs
Valeo Pharma Inc. stock logo
VPH
Valeo Pharma
C$0.00
C$0.04
▼
C$0.39
C$4.44M2.3259,093 shs51,000 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entegris, Inc. stock logo
ENTG
Entegris
-4.06%-9.45%+13.29%+5.86%+55.22%
LBL
Lattice Biologics
0.00%0.00%0.00%0.00%0.00%
Indiva Limited stock logo
NDVA
Indiva
0.00%0.00%0.00%0.00%0.00%
Valeo Pharma Inc. stock logo
VPH
Valeo Pharma
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entegris, Inc. stock logo
ENTG
Entegris
$138.74
-5.5%		$147.53
$67.97
▼
$186.94
$22.40B1.42.22 million shs2.71 million shs
LBL
Lattice Biologics
C$0.04
C$0.04
C$0.03
▼
C$0.13
C$5.13MN/A468,022 shs114,000 shs
Indiva Limited stock logo
NDVA
Indiva
C$0.03
-14.3%		C$0.03
C$0.02
▼
C$0.13
C$5.87M1.12119,038 shs558,384 shs
Valeo Pharma Inc. stock logo
VPH
Valeo Pharma
C$0.00
C$0.04
▼
C$0.39
C$4.44M2.3259,093 shs51,000 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entegris, Inc. stock logo
ENTG
Entegris
-4.06%-9.45%+13.29%+5.86%+55.22%
LBL
Lattice Biologics
0.00%0.00%0.00%0.00%0.00%
Indiva Limited stock logo
NDVA
Indiva
0.00%0.00%0.00%0.00%0.00%
Valeo Pharma Inc. stock logo
VPH
Valeo Pharma
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Entegris, Inc. stock logo
ENTG
Entegris
3.00
Buy$178.3328.54% Upside
LBL
Lattice Biologics
0.00
N/AN/AN/A
Indiva Limited stock logo
NDVA
Indiva
0.00
N/AN/AN/A
Valeo Pharma Inc. stock logo
VPH
Valeo Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ENTG, NDVA, LBL, and VPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/14/2026
Entegris, Inc. stock logo
ENTG
Entegris
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$190.00
10/12/2026
Entegris, Inc. stock logo
ENTG
Entegris
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOverweight$212.00
10/12/2026
Entegris, Inc. stock logo
ENTG
Entegris
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong-Buy
10/7/2026
Entegris, Inc. stock logo
ENTG
Entegris
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$200.00
10/7/2026
Entegris, Inc. stock logo
ENTG
Entegris
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeStrong-Buy ➝ Hold
8/12/2026
Entegris, Inc. stock logo
ENTG
Entegris
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell ➝ Buy
8/12/2026
Entegris, Inc. stock logo
ENTG
Entegris
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Buy$152.00 ➝ $200.00
8/5/2026
Entegris, Inc. stock logo
ENTG
Entegris
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$152.00
8/5/2026
Entegris, Inc. stock logo
ENTG
Entegris
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$205.00 ➝ $215.00
8/5/2026
Entegris, Inc. stock logo
ENTG
Entegris
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Strong-Buy
(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Entegris, Inc. stock logo
ENTG
Entegris
$3.20B6.62$5.12 per share27.08$26.08 per share5.32
LBL
Lattice Biologics
C$1.56M3.29N/AN/AC$0.00 per share40.00
Indiva Limited stock logo
NDVA
Indiva
C$37.57M0.16C$0.01 per share5.20N/A∞
Valeo Pharma Inc. stock logo
VPH
Valeo Pharma
C$53.38M0.00N/AN/AC($0.64) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Entegris, Inc. stock logo
ENTG
Entegris
$235.60M$1.9969.7227.921.359.18%12.25%5.84%10/29/2026 (Estimated)
LBL
Lattice Biologics
N/A-C$0.01N/AN/AN/AN/AN/AN/AN/A
Indiva Limited stock logo
NDVA
Indiva
-C$4.92M-C$0.03N/AN/AN/A-13.09%-544.76%-3.51%N/A
Valeo Pharma Inc. stock logo
VPH
Valeo Pharma
-C$32.12M-C$0.37N/AN/AN/A-60.18%N/A-26.07%N/A

Latest ENTG, NDVA, LBL, and VPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Entegris, Inc. stock logo
ENTG
Entegris
$1.02N/AN/AN/A$924.49 millionN/A
8/4/2026Q2 2026
Entegris, Inc. stock logo
ENTG
Entegris
$0.8220$0.93+$0.1080$0.61$835.79 million$883.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Entegris, Inc. stock logo
ENTG
Entegris
$0.400.29%+4.56%20.10%N/A
LBL
Lattice Biologics
N/AN/AN/AN/AN/A
Indiva Limited stock logo
NDVA
Indiva
N/A4.04%N/AN/AN/A
Valeo Pharma Inc. stock logo
VPH
Valeo Pharma
N/AN/AN/AN/AN/A

Latest ENTG, NDVA, LBL, and VPH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/14/2026
Entegris, Inc. stock logo
ENTG
Entegris
quarterly$0.100.26%10/28/202610/28/202611/18/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Entegris, Inc. stock logo
ENTG
Entegris
0.83
3.05
1.85
LBL
Lattice Biologics
N/A
0.02
0.02
Indiva Limited stock logo
NDVA
Indiva
5,899.22
0.72
0.52
Valeo Pharma Inc. stock logo
VPH
Valeo Pharma
N/A
0.27
N/A

Institutional Ownership

CompanyInstitutional Ownership
Entegris, Inc. stock logo
ENTG
Entegris
N/A
LBL
Lattice Biologics
N/A
Indiva Limited stock logo
NDVA
Indiva
0.06%
Valeo Pharma Inc. stock logo
VPH
Valeo Pharma
7.24%

Insider Ownership

CompanyInsider Ownership
Entegris, Inc. stock logo
ENTG
Entegris
0.53%
LBL
Lattice Biologics
N/A
Indiva Limited stock logo
NDVA
Indiva
36.29%
Valeo Pharma Inc. stock logo
VPH
Valeo Pharma
47.12%
CompanyEmployeesShares OutstandingFree FloatOptionable
Entegris, Inc. stock logo
ENTG
Entegris
7,700152.50 million151.69 millionOptionable
LBL
Lattice Biologics
N/A128.22 millionN/ANot Optionable
Indiva Limited stock logo
NDVA
Indiva
147,000195.49 millionN/ANot Optionable
Valeo Pharma Inc. stock logo
VPH
Valeo Pharma
10098.66 millionN/ANot Optionable

Recent News About These Companies

Acesis Biomed Appoints Dr. Frederic Fasano, Pharm.D, MBA, ICD.D to the Board of Directors as Chairman
September 9, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/acesis-biomed-appoints-dr-frederic-fasano-pharm-d-mba-icd-d-to-the-board-of-directors-as-chairman-1035128904
Valeo Pharma announces the closing of a share purchase agreement with Xediton Pharmaceuticals Inc.
February 6, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/valeo-pharma-announces-closing-share-002700173.html
Valeo: Weak Auto Markets And EV Uncertainties Continue To Hit Hard
October 31, 2024  |  seekingalpha.comhttps://seekingalpha.com/article/4731478-valeo-weak-auto-markets-and-ev-uncertainties-continue-to-hit-hard
Valeo Pharma Inc.: Valeo Pharma Reports Third Quarter 2024 Revenues
October 5, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-09/63423577-valeo-pharma-inc-valeo-pharma-reports-third-quarter-2024-revenues-008.htm
Canadian Investment Regulatory Organization Trading Halt - VPH
October 2, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/canadian-investment-regulatory-organization-trading-121100725.html
VALEO PHARMA INITIATES RESTRUCTURING PROCEEDINGS UNDER THE CCAA TO IMPLEMENT A REVIEW OF ITS STRATEGIC ALTERNATIVES
October 1, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/valeo-pharma-initiates-restructuring-proceedings-235000037.html
VALEO PHARMA REPORTS THIRD QUARTER 2024 REVENUES
September 13, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/valeo-pharma-reports-third-quarter-203000298.html
VALEO PHARMA TO HOST THIRD QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST
September 9, 2024  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/news/valeo-pharma-host-third-quarter-110000225.html
Valeo Pharma Inc. (VPH.TO)
September 6, 2024  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/quote/VPH.TO/chart/
Bay Street Likely To Open On Weak Note
September 4, 2024  |  nasdaq.comhttps://www.nasdaq.com/articles/bay-street-likely-open-weak-note-1
VALEO PHARMA AMENDS CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP
September 4, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/valeo-pharma-amends-credit-facility-110000339.html
VALEO PHARMA ANNOUNCES VOLUNTARY DELISTING FROM OTCQB VENTURE MARKET
August 29, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/valeo-pharma-announces-voluntary-delisting-110000604.html
VALEO PHARMA ANNOUNCES LEADERSHIP CHANGES
August 6, 2024  |  newswire.cahttps://www.newswire.ca/news-releases/valeo-pharma-announces-leadership-changes-815246907.html
Closing Bell: Valeo Pharma Inc 12.0 Pct Debs down on Monday (VPH-DB)
July 20, 2024  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VPH-DB-T/pressreleases/27502451/closing-bell-valeo-pharma-inc-120-pct-debs-down-on-monday-vph-db/
Bullish Valeo Pharma Insiders Loaded Up On CA$1.20m Of Stock
May 5, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/bullish-valeo-pharma-insiders-loaded-122612624.html?.tsrc=rss
News Flash: 2 Analysts Think Valeo Pharma Inc. (TSE:VPH) Earnings Are Under Threat
February 14, 2024  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/news-flash-2-analysts-think-182726639.html
VALEO PHARMA ANNOUNCES BOARD OF DIRECTORS CHANGES
February 13, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/valeo-pharma-announces-board-directors-120000894.html?.tsrc=rss
Biden to release proposed U.S. budget plan on March 11
February 3, 2024  |  msn.comhttps://www.msn.com/he-il/news/other/biden-to-release-proposed-u-s-budget-plan-on-march-11/ar-BB1hGXUm
VALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP
February 2, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/valeo-pharma-amends-agreement-novartis-220300003.html?.tsrc=rss
VALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL YEAR 2023
January 29, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/valeo-pharma-reports-record-annual-224800042.html?.tsrc=rss

New MarketBeat Followers Over Time

Media Sentiment Over Time

Entegris stock logo

Entegris NASDAQ:ENTG

$138.74 -8.13 (-5.54%)
Closing price 04:00 PM Eastern
Extended Trading
$136.94 -1.80 (-1.30%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Entegris, Inc. develops, manufactures, and supplies microcontamination control products, specialty chemicals, and advanced materials handling solutions in North America, Taiwan, China, South Korea, Japan, Europe, and Southeast Asia. It operates in three segments: Materials Solutions (MS); Microcontamination Control (MC); and Advanced Materials Handling (AMH). The MC segment solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries; integrated circuit chemical mechanical polishing solutions, high-performance etch and clean chemistries, gases and materials, and safe and materials delivery systems. The MS segment provides materials-based solutions, such as chemical mechanical planarization slurries, pads, deposition materials, process chemistries and gases, formulated cleans, etchants, and other specialty materials. The Advanced Materials Handling segment develops solutions for customers' yields by protecting critical materials during manufacturing, transportation, and storage, which include monitor, protect, transport and deliver critical liquid chemistries, wafers, and other substrates for semiconductor, life sciences and other high-technology industries. The company's customers include logic and memory semiconductor device manufacturers, semiconductor equipment makers, gas and chemical manufacturing companies, and wafer grower companies; and flat panel display equipment makers, panel manufacturers, and manufacturers of hard disk drive components and devices, as well as their related ecosystems. It serves manufacturers and suppliers in the solar and life science industries, electrical discharge machining customers, glass and glass container manufacturers, aerospace manufacturers, and manufacturers of biomedical implantation devices. Entegris, Inc. was founded in 1966 and is headquartered in Billerica, Massachusetts.

Lattice Biologics CVE:LBL

C$0.04 0.00 (0.00%)
As of 06/3/2021

Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops novel amniotic fluid-based products, such as AmnioBoost and AmnioBlast. The company also offers traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, hernia repair, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior and posterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.

Indiva stock logo

Indiva CVE:NDVA

C$0.03 -0.01 (-14.29%)
As of 06/12/2024

Indiva Limited engages in the production, processing, and sale of cannabis and cannabis related products in Canada. It offers pre-rolls, flower, capsules, and edible and extract products under the INDIVA, Indiva Life, and Artisan Batch brands. The company produces and distributes the Bhang Chocolate, Wana Sour Gummies, Jewels Chewable Tarts, Grön edibles, and Dime Industries vape products through license agreements and partnerships. Indiva Limited is based in Ottawa, Canada.

Valeo Pharma stock logo

Valeo Pharma TSE:VPH

Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas